Crumly & Associates Inc. Biomarin Pharmaceutical Inc Transaction History

Crumly & Associates Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$71.48 - $86.85 $417,371 - $507,117	-5,839 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$74.28 - $92.69 $6,759 - $8,434	91 Added 1.58%	5,839 $450,000
Q4 2021 Feb 04, 2022	BUY	$71.72 - $91.47 $115,684 - $147,541	1,613 Added 39.01%	5,748 $505,000
Q3 2021 Oct 20, 2021	SELL	$74.77 - $85.47 $196,196 - $224,273	-2,624 Reduced 38.82%	4,135 $320,000
Q2 2021 Aug 09, 2021	SELL	$75.51 - $84.79 $58,822 - $66,051	-779 Reduced 10.33%	6,759 $564,000
Q1 2021 Apr 27, 2021	BUY	$74.73 - $90.69 $257,519 - $312,517	3,446 Added 84.21%	7,538 $569,000
Q4 2020 Jan 25, 2021	SELL	$72.61 - $90.2 $22,073 - $27,420	-304 Reduced 6.92%	4,092 $360,000
Q3 2020 Oct 21, 2020	BUY	$71.87 - $131.03 $315,940 - $576,007	4,396 New	4,396 $334,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Crumly & Associates Inc., based on Form 13F filings with the SEC.

Stay updated on Crumly & Associates Inc. with notifications on news.